Eli Lilly & Co. (LLY) – Globe Newswire
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
-
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
-
Lilly and ProQR to Expand RNA Editing Collaboration
-
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results
-
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
-
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
-
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
-
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
-
Distribution of Etesevimab/JS016 in the US Reopened
-
Distribution of Etesevimab/JS016 in the US Reopened
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
-
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
-
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
-
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
-
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
-
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
-
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
-
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
-
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
-
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
-
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
-
Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multipl
-
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
-
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
-
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds R, ELAN, FSCT and ENPH Shareholders of Important Class Action Deadlines
-
PetIQ, Inc. Receives FTC Approval to Close Acquisition of the Capstar® Portfolio of Products
-
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds LOPE, R, ELAN and WFC Shareholders of Important Class Action Deadlines
-
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds LOPE, R, ELAN and WFC Shareholders of Important Class Action Deadlines
-
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds ELAN, FSCT, PRA and USO Shareholders of Important Class Action Deadlines
-
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
-
ELAN Class Action Deadline: Barbuto & Johansson, P.A. Reminds Elanco Animal Health, Inc. Shareholders of Important Deadline in the Recently Filed Securities Class Action
-
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
-
EULAR 2020: Lilly Shares New Data for OLUMIANT® in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)
-
Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China
-
Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China
-
EULAR 2020: Lilly’s TALTZ® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis
-
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies
-
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies
-
Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
-
Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
-
The Elanco Foundation Announces Efforts to Support Food Security Amidst COVID-19 Crisis
-
Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti
-
Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
-
Ready for Rescue – New Nasally Administered Glucagon for Severe Hypoglycemia Available in Canada
-
PetIQ, Inc. Enters Into Definitive Agreement to Acquire the Capstar® portfolio of products from Elanco
-
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from TALTZ® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
-
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of TALTZ® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Back to LLY Stock Lookup
